| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accurate accounting of caplacizumab cost effectiveness
|
Goshua, George
|
|
|
|
5 |
p. e315
|
artikel
|
| 2 |
Accurate accounting of caplacizumab cost effectiveness – Authors' reply
|
Hughes, Mary
|
|
|
|
5 |
p. e316
|
artikel
|
| 3 |
Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells
|
Rushworth, Stuart A
|
|
2015
|
|
5 |
p. e204-e211
nvt p.
|
artikel
|
| 4 |
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis
|
Bucher, Christoph
|
|
|
|
5 |
p. e364
|
artikel
|
| 5 |
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis – Authors' reply
|
Walker, Irwin
|
|
|
|
5 |
p. e364-e365
|
artikel
|
| 6 |
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
|
Risitano, Antonio M
|
|
|
|
5 |
p. e344-e354
|
artikel
|
| 7 |
Advancement in monoclonal antibody therapy for multiple myeloma
|
Shigle, Terri Lynn
|
|
|
|
5 |
p. e354-e355
|
artikel
|
| 8 |
A long-awaited benchmark in lymphomatoid granulomatosis
|
Peters, Anthea
|
|
|
|
5 |
p. e311-e312
|
artikel
|
| 9 |
Analysis of big data for heparin-induced thrombocytopenia: valuable information but also some doubts
|
Gruel, Yves
|
|
2018
|
|
5 |
p. e188-e189
|
artikel
|
| 10 |
Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen?
|
D'Agostino, Mattia
|
|
|
|
5 |
p. e355-e357
|
artikel
|
| 11 |
Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association
|
Stemler, Jannik
|
|
|
|
5 |
p. e361-e373
|
artikel
|
| 12 |
Approaches to measure paediatric chemotherapy-induced peripheral neurotoxicity: a systematic review
|
Smith, Ellen M Lavoie
|
|
|
|
5 |
p. e408-e417
|
artikel
|
| 13 |
A probable case of aggressive extranodal natural killer T-cell lymphoma in a 19th century Qing Dynasty painting
|
Fan, Bingwen Eugene
|
|
|
|
5 |
p. e321-e322
|
artikel
|
| 14 |
Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis
|
Admiraal, Rick
|
|
2015
|
|
5 |
p. e194-e203
nvt p.
|
artikel
|
| 15 |
ATG in paediatric haemopoietic stem cell transplantation
|
Diaz, Miguel A
|
|
2015
|
|
5 |
p. e178-e179
nvt p.
|
artikel
|
| 16 |
Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19
|
Wang, Tao
|
|
|
|
5 |
p. e362-e363
|
artikel
|
| 17 |
BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?
|
Soverini, Simona
|
|
2019
|
|
5 |
p. e236-e237
|
artikel
|
| 18 |
Blood in the bookshop
|
Ranscombe, Peter
|
|
2016
|
|
5 |
p. e214-
1 p.
|
artikel
|
| 19 |
Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?
|
Shah, Niketa C
|
|
|
|
5 |
p. e309-e311
|
artikel
|
| 20 |
Challenges in the development of bispecific antibodies for non-Hodgkin lymphoma
|
Dickinson, Michael
|
|
|
|
5 |
p. e314-e315
|
artikel
|
| 21 |
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
|
Ferreri, Andrés J M
|
|
2016
|
|
5 |
p. e217-e227
nvt p.
|
artikel
|
| 22 |
Chen Saijuan: from textile mill worker to haematologist
|
Kirby, Tony
|
|
|
|
5 |
p. 320
|
artikel
|
| 23 |
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial
|
Gleeson, Mary
|
|
2018
|
|
5 |
p. e190-e200
|
artikel
|
| 24 |
Chronic myeloid leukaemia: time to push for a cure?
|
The Lancet Haematology,
|
|
2015
|
|
5 |
p. e175-
1 p.
|
artikel
|
| 25 |
Clinical associations of CSNK1A1 mutation in myelodysplastic syndrome
|
Boultwood, Jacqueline
|
|
2015
|
|
5 |
p. e182-e183
nvt p.
|
artikel
|
| 26 |
Clinical trial material
|
Costa, Luciano J
|
|
|
|
5 |
p. e368
|
artikel
|
| 27 |
CML and tyrosine kinase inhibition: the hope becomes reality
|
Apperley, Jane F
|
|
2015
|
|
5 |
p. e176-e177
nvt p.
|
artikel
|
| 28 |
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial
|
Bashir, Qaiser
|
|
2019
|
|
5 |
p. e266-e275
|
artikel
|
| 29 |
Conservation of the group O, Rhesus D negative blood supply
|
Uhl, Lynne
|
|
|
|
5 |
p. e195-e196
|
artikel
|
| 30 |
Correction to Lancet Haematol 2015; 2: e93
|
|
|
2015
|
|
5 |
p. e184-
1 p.
|
artikel
|
| 31 |
Correction to Lancet Haematol 2019; 6: e183–93
|
|
|
2019
|
|
5 |
p. e238
|
artikel
|
| 32 |
Correction to Lancet Haematol 2017; 4: e202–17
|
|
|
|
|
5 |
p. e201
|
artikel
|
| 33 |
Correction to Lancet Haematol 2017: 4: e183–91
|
|
|
|
|
5 |
p. e201
|
artikel
|
| 34 |
Correction to Lancet Haematol 2017; 4: e154–55
|
|
|
|
|
5 |
p. e201
|
artikel
|
| 35 |
COVID-19 vaccines: building and maintaining confidence
|
The Lancet Haematology,
|
|
|
|
5 |
p. e305
|
artikel
|
| 36 |
COVID-19 vaccines for patients with haematological conditions
|
Sun, Clare
|
|
|
|
5 |
p. e312-e314
|
artikel
|
| 37 |
CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis
|
Smith, Alexander E
|
|
2015
|
|
5 |
p. e212-e221
nvt p.
|
artikel
|
| 38 |
Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial
|
Grupp, Stephan A
|
|
|
|
5 |
p. e333-e345
|
artikel
|
| 39 |
Defining clinically relevant measures of iron overload around haemopoietic stem cell transplantation
|
Leitch, Heather A
|
|
2018
|
|
5 |
p. e184-e185
|
artikel
|
| 40 |
Defining optimal initial therapy for primary CNS lymphoma
|
Schiff, David
|
|
2016
|
|
5 |
p. e206-e207
nvt p.
|
artikel
|
| 41 |
Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study
|
Dhakal, Binod
|
|
2018
|
|
5 |
p. e220-e231
|
artikel
|
| 42 |
Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma?
|
David, Kevin A
|
|
2018
|
|
5 |
p. e186-e187
|
artikel
|
| 43 |
Edoxaban in the secondary prevention of VTE
|
Levy, Jerrold H
|
|
2016
|
|
5 |
p. e208-e209
nvt p.
|
artikel
|
| 44 |
Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study
|
Larsen, Torben B
|
|
|
|
5 |
p. e237-e244
|
artikel
|
| 45 |
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study
|
Kizilors, Aytug
|
|
2019
|
|
5 |
p. e276-e284
|
artikel
|
| 46 |
Emergency transfusion of patients with unknown blood type with blood group O Rhesus D positive red blood cell concentrates: a prospective, single-centre, observational study
|
Selleng, Kathleen
|
|
|
|
5 |
p. e218-e224
|
artikel
|
| 47 |
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial
|
Wermke, Martin
|
|
2018
|
|
5 |
p. e201-e210
|
artikel
|
| 48 |
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy
|
Mariotte, Eric
|
|
2016
|
|
5 |
p. e237-e245
nvt p.
|
artikel
|
| 49 |
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
|
Nanni, Cristina
|
|
|
|
5 |
p. e367-e381
|
artikel
|
| 50 |
Exposure to Coxiella burnetii and risk of non-Hodgkin lymphoma: a retrospective population-based analysis in the Netherlands
|
van Roeden, Sonja E
|
|
2018
|
|
5 |
p. e211-e219
|
artikel
|
| 51 |
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study
|
Raskob, Gary
|
|
2016
|
|
5 |
p. e228-e236
nvt p.
|
artikel
|
| 52 |
Factor B inhibition for paroxysmal nocturnal haemoglobinuria
|
Brodsky, Robert A
|
|
|
|
5 |
p. e309-e310
|
artikel
|
| 53 |
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial
|
Srivastava, Alok
|
|
|
|
5 |
p. e322-e332
|
artikel
|
| 54 |
Fitusiran prophylaxis in severe haemophilia without inhibitors
|
Jiménez-Yuste, Víctor
|
|
|
|
5 |
p. e308-e309
|
artikel
|
| 55 |
Forging a path for chronic myelomonocytic leukaemia
|
The Lancet Haematology,
|
|
2019
|
|
5 |
p. e229
|
artikel
|
| 56 |
Further investment for cancer reduction in the USA
|
The Lancet Haematology,
|
|
|
|
5 |
p. e307
|
artikel
|
| 57 |
Gene therapy for Wiskott-Aldrich syndrome: here to stay
|
Candotti, Fabio
|
|
2019
|
|
5 |
p. e230-e231
|
artikel
|
| 58 |
Global improvements in childhood leukaemia survival
|
The Lancet Haematology,
|
|
|
|
5 |
p. e192
|
artikel
|
| 59 |
Handling the COVID-19 pandemic in the oncological setting
|
Mussetti, Alberto
|
|
|
|
5 |
p. e365-e366
|
artikel
|
| 60 |
Ibrutinib for AML? Check CD117 (KIT)!
|
Spaargaren, Marcel
|
|
2015
|
|
5 |
p. e180-e181
nvt p.
|
artikel
|
| 61 |
Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT
|
Leclerc, Mathieu
|
|
|
|
5 |
p. e318-e321
|
artikel
|
| 62 |
Improving the conditioning regimen in multiple myeloma
|
Mateos, María-Victoria
|
|
2019
|
|
5 |
p. e234-e235
|
artikel
|
| 63 |
Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study
|
Wiegers, Hanke M G
|
|
|
|
5 |
p. e359-e366
|
artikel
|
| 64 |
Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial
|
Melani, Christopher
|
|
|
|
5 |
p. e346-e358
|
artikel
|
| 65 |
Is complete remission key in elderly patients with AML?
|
Ferrara, Felicetto
|
|
2016
|
|
5 |
p. e212-e213
nvt p.
|
artikel
|
| 66 |
Issues raised by the incidence and survival of childhood cancers
|
Autier, Philippe
|
|
|
|
5 |
p. e193-e194
|
artikel
|
| 67 |
Is there a role for new drugs with alkylating properties in multiple myeloma?
|
Mateos, María-Victoria
|
|
|
|
5 |
p. e357-e359
|
artikel
|
| 68 |
Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study
|
Ferrua, Francesca
|
|
2019
|
|
5 |
p. e239-e253
|
artikel
|
| 69 |
Life beyond blood disorders
|
Chakrabarti, Prantar
|
|
|
|
5 |
p. e320-e321
|
artikel
|
| 70 |
Making blood count
|
The Lancet Haematology,
|
|
|
|
5 |
p. e307
|
artikel
|
| 71 |
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study
|
Richardson, Paul G
|
|
|
|
5 |
p. e395-e407
|
artikel
|
| 72 |
Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee
|
Cliff, Edward R Scheffer
|
|
|
|
5 |
p. e314-e317
|
artikel
|
| 73 |
MGIP, MGUS, and the PROMISE of meaning in small things
|
D'Souza, Anita
|
|
|
|
5 |
p. e315-e317
|
artikel
|
| 74 |
Monoclonal antibody-drug conjugates in B-cell lymphomas
|
Chiappella, Annalisa
|
|
2019
|
|
5 |
p. e232-e233
|
artikel
|
| 75 |
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
|
Raab, Marc S
|
|
|
|
5 |
p. e381-e394
|
artikel
|
| 76 |
42nd Annual Meeting of the European Society for Blood and Marrow Transplantation
|
Smith, Lan-Lan
|
|
2016
|
|
5 |
p. e215-e216
nvt p.
|
artikel
|
| 77 |
Ocular involvement in extranodal natural-killer T-cell lymphoma
|
Yang, Peizeng
|
|
|
|
5 |
p. e382
|
artikel
|
| 78 |
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
|
Bannerji, Rajat
|
|
|
|
5 |
p. e327-e339
|
artikel
|
| 79 |
Ongoing humanitarian crisis in Ukraine
|
The Lancet Haematology,
|
|
|
|
5 |
p. e313
|
artikel
|
| 80 |
Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP
|
Wilcox, Ryan A
|
|
2018
|
|
5 |
p. e182-e183
|
artikel
|
| 81 |
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
|
Azoulay, Élie
|
|
|
|
5 |
p. e355-e364
|
artikel
|
| 82 |
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
|
Mesa, Ruben A
|
|
|
|
5 |
p. e225-e236
|
artikel
|
| 83 |
Patients with haematological malignancies should not have to choose between transfusions and hospice care
|
Odejide, Oreofe O
|
|
|
|
5 |
p. e418-e424
|
artikel
|
| 84 |
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
|
Morschhauser, Franck
|
|
2019
|
|
5 |
p. e254-e265
|
artikel
|
| 85 |
Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management
|
Zhao, Eric J
|
|
|
|
5 |
p. e365-e375
|
artikel
|
| 86 |
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study
|
El-Khoury, Habib
|
|
|
|
5 |
p. e340-e349
|
artikel
|
| 87 |
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
|
Thanarajasingam, Gita
|
|
|
|
5 |
p. e374-e384
|
artikel
|
| 88 |
Recognising inequalities in haematopoietic stem-cell transplantation and cellular therapy training
|
Horgan, Claire
|
|
|
|
5 |
p. e323-e324
|
artikel
|
| 89 |
Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study
|
Heddle, Nancy M
|
|
2016
|
|
5 |
p. e246-e254
nvt p.
|
artikel
|
| 90 |
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
|
Sasaki, Koji
|
|
2015
|
|
5 |
p. e186-e193
nvt p.
|
artikel
|
| 91 |
Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
|
Biemond, Bart J
|
|
|
|
5 |
p. e334-e343
|
artikel
|
| 92 |
Sevuparin trial for acute pain in sickle cell disease: the dog that did not bark
|
Ellsworth, Patrick
|
|
|
|
5 |
p. e307-e309
|
artikel
|
| 93 |
Shaping cancer policy to work towards the interests of patients
|
Burki, Talha K
|
|
|
|
5 |
p. e369
|
artikel
|
| 94 |
Strategic plan for management of COVID-19 in paediatric haematology and oncology departments
|
He, Yulei
|
|
|
|
5 |
p. e359-e362
|
artikel
|
| 95 |
Straying from the target
|
The Lancet Haematology,
|
|
2016
|
|
5 |
p. e205-
1 p.
|
artikel
|
| 96 |
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
|
Mateos, Maria-Victoria
|
|
|
|
5 |
p. e370-e380
|
artikel
|
| 97 |
Sugar, video games, and VTE: an unseen connection?
|
The Lancet Haematology,
|
|
2018
|
|
5 |
p. e181
|
artikel
|
| 98 |
Superficial vein thrombosis in pregnancy: what we did not know could hurt our patients
|
Bates, Shannon M
|
|
|
|
5 |
p. e313-e314
|
artikel
|
| 99 |
Surviving the storm: critical care outcomes of chimeric antigen receptor T-cell therapy
|
Athale, Janhavi
|
|
|
|
5 |
p. e311-e312
|
artikel
|
| 100 |
Telemedicine for rural and regional patient access to haematology services during the COVID-19 pandemic in Australia
|
Cashman, Helen
|
|
|
|
5 |
p. e325-e326
|
artikel
|
| 101 |
48th Annual Meeting of the EBMT
|
Cookson, Emma
|
|
|
|
5 |
p. e322
|
artikel
|
| 102 |
47th Annual Meeting of the EBMT
|
del Pozo Martín, Yaiza
|
|
|
|
5 |
p. e317-e318
|
artikel
|
| 103 |
55th Annual Scientific Meeting of the BSH
|
Yaqub, Farhat
|
|
2015
|
|
5 |
p. e185-
1 p.
|
artikel
|
| 104 |
The changing face of haemophilia care in Pakistan
|
Tariq, Rabbia
|
|
|
|
5 |
p. e319
|
artikel
|
| 105 |
The lure and pitfalls of administrative health registers
|
Johnsen, Søren Paaske
|
|
|
|
5 |
p. e199-e200
|
artikel
|
| 106 |
The power of specialty palliative care: moving towards a systems perspective
|
Barnato, Amber E
|
|
|
|
5 |
p. e376-e381
|
artikel
|
| 107 |
The resurgence of convalescent plasma therapy
|
The Lancet Haematology,
|
|
|
|
5 |
p. e353
|
artikel
|
| 108 |
The value of teaching the influence of sex and gender on health outcomes
|
Martin, Kelsey
|
|
|
|
5 |
p. e318-e319
|
artikel
|
| 109 |
Thrombotic thrombocytopenic purpura: gaining knowledge
|
Bennett, Charles L
|
|
2016
|
|
5 |
p. e210-e211
nvt p.
|
artikel
|
| 110 |
Transgender health and haematology—a matter of respect
|
Connors, Jean M
|
|
|
|
5 |
p. e367
|
artikel
|
| 111 |
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past
|
Short, Nicholas J
|
|
|
|
5 |
p. e382-e388
|
artikel
|
| 112 |
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
|
Lachowiez, Curtis A
|
|
|
|
5 |
p. e350-e360
|
artikel
|
| 113 |
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia
|
Juliusson, Gunnar
|
|
|
|
5 |
p. e317-e318
|
artikel
|
| 114 |
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial
|
Howard, Jo
|
|
|
|
5 |
p. e323-e333
|
artikel
|
| 115 |
What should be the endpoints of a symptomatic drug and its control?
|
Leone, Giuseppe
|
|
|
|
5 |
p. e197-e198
|
artikel
|
| 116 |
Will the changing therapeutic landscape meet the needs of patients with sickle cell disease?
|
Inusa, Baba Psalm Duniya
|
|
|
|
5 |
p. e306-e307
|
artikel
|
| 117 |
Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries
|
Bonaventure, Audrey
|
|
|
|
5 |
p. e202-e217
|
artikel
|
Tijdschrift beschrijving